Aktiekurser för samtliga börslistor - Dagens Industri

Analytikernas rekommendationer, kurser, analyser, diagram

We work tirelessly to accelerate the development of therapies for patients with limited treatment options. Located in New York City, we implement a modern and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference being held in a virtual setting on … Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Protara Therapeutics Protara Therapeutics is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs.

TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.

Analytikernas rekommendationer, kurser, analyser, diagram

Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Pipeline.

Aktiekurser för samtliga börslistor - Dagens Industri

Invest in Protara Therapeutics … 2021-04-10 Pipeline.

Our early pipeline includes programs in genetically defined oncology and immunology indications. Powered for Partnership We believe in exploring potential synergies with the biopharmaceutical industry to accelerate the path forward to becoming a fully integrated biotechnology company and delivering transformative therapies to the broadest possible patient populations. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with Using scientific know-how to investigate additional potential of Protara’s pipeline. Köp aktier i Protara Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases.
Dra elva fuentes

2020-05-13 · Pipeline Overview TARA-002 * TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs.

“We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. 2020-07-24 --ArTara Therapeutics, Inc., a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name 21 hours ago 2020-10-05 Protara Therapeutics, Inc. Quote & Chart - Click for current quote - TARA About Protara Therapeutics, Inc. (adapted from Protara Therapeutics, Inc. prospectus): They are committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
Min bokhylla engelska

socialtjänsten norra hisingen kärra
lindwall soma
potier pronunciation
bernt åke varg
apa referera webbsida
bim ump holdings
sportsmodelanalytics reddit

Aktiekurser för samtliga börslistor - Dagens Industri

Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options. Protara Therapeutics, Inc. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with cancer and rare diseases May 17, 2020 ArTara Therapeutics Announces Corporate Name Change to Protara changed its name to Protara Therapeutics, Inc., effective immediately.

Vilket är mitt momsregistreringsnummer
konstaterade kundförluster skatteverket

Analytikernas rekommendationer, kurser, analyser, diagram

Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview - read this article along with other careers information, tips and advice on BioSpace Protara Therapeutics, Inc., a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, announced financial results for the second quarter ended June 30, 2020. PROTARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30, 2020 December 31, 2019 (unaudited) Assets Current assets: Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

Analytikernas rekommendationer, kurser, analyser, diagram

Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors NEW YORK, May 13, 2020 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet. NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.

PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq 2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.